Metagenomi Therapeutics annual shares outstanding
2022
2023
2024
2025
Metagenomi Therapeutics Shares Outstanding History (MGX)
Metagenomi Therapeutics reported 37.6M shares outstanding at the end of fiscal 2025.
View full Metagenomi Therapeutics company overviewMetagenomi Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 37.6M | 202,198 | +0.54% |
| 2024 | 2024-12-31 | 37.4M | 34.0M | +999.06% |
| 2023 | 2023-12-31 | 3.4M | −34.1M | −90.93% |
| 2022 | 2022-12-31 | 37.5M | — | — |
Metagenomi Therapeutics quarterly shares outstanding
Q4.23
As of Jan 24, 2024
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 37.8M | 243,969 | +0.65% |
| Q1 2026 | 2026-03-31 | 37.6M | 264,579 | +0.71% |
| Q4 2025 | 2025-12-31 | 37.6M | 202,198 | +0.54% |
| Q3 2025 | 2025-09-30 | 37.5M | 113,919 | +0.30% |
| Q2 2025 | 2025-06-30 | 37.5M | 73,283 | +0.20% |
| Q1 2025 | 2025-03-31 | 37.4M | −85,600 | −0.23% |
| Q4 2024 | 2024-12-31 | 37.4M | 34.0M | +999.06% |
| Q3 2024 | 2024-09-30 | 37.4M | — | — |
| Q2 2024 | 2024-06-30 | 37.5M | — | — |
| Q1 2024 | 2024-03-31 | 37.5M | — | — |
| As of Jan 24, 2024 | 2024-01-24 | 37.4M | — | — |
| Q4 2023 | 2023-12-31 | 3.4M | — | — |
Metagenomi Therapeutics shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Metagenomi Therapeutics's shares outstanding moved from 37.5M to 37.6M, a change of 92,973. The latest reported quarter, Q2 2026, shows 37.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Metagenomi Therapeutics source filings ↗